1. Clovis Oncology reports TIGER2 cancer study has begun with dosing of first patient in U.S.

    Clovis Oncology reports TIGER2 cancer study has begun with dosing of first patient in U.S.

    Clovis Oncology reports TIGER2 cancer study has begun with dosing of first enrolled patient in U.S.

    0 23 Jun 2014 Boulder, Clovis Oncology, CO-1686, Lecia Sequist, Patrick J.Mahaffy, TIGER2 by InnovatioNews

    Clovis- Oncology logo BOULDER – Clovis Oncology Inc. (NASDAQ: CLVS) today announced its TIGER2 cancer study has commenced with the dosing of the first patient at a U.S. study site.

    Read Full Article
  1. Quotes

    1. In the clinic, we are seeing an increasingly acute need for effective treatments against T790M.
    2. We are pleased to begin enrolling TIGER2, our registration study for CO-1686 focused on T790M-positive patients who have progressed following their first EFGR-targeted therapy.
  2. Authors

  3. Categories

    1. Feeds:

      CTA Members Press Releases, CTA Tech Tour, Government & Policy, Tech Workforce & Education
    2. Tags:

      B2B Software, Big Data & Analytics, Business Services Provider, Cloud, Community Organizations, Consumer Software, Development, Energy Tech, Enterprise, Government, Hardware, Health IT, Innovation & Entrepreneurship, Internet of Things, Mobile, Security, Startups, Telecom, Women In Tech